- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06816524
The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency
The Effects of Iron Treatment on Malaria, Typhoid and Measles Vaccine Response in Kenyan Infants With Iron Deficiency: A Randomized Controlled Trial
Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination.
In this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21/Matrix-M, Typhim VI and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Nicole Stoffel, PhD
- Telefonnummer: +41 044 632 83 93
- E-Mail: nicole.stoffel@hest.ethz.ch
Studieren Sie die Kontaktsicherung
- Name: Lara Del Curto, MSc
- Telefonnummer: +41 0774212070
- E-Mail: lara.delcurto@pharma.ethz.ch
Studienorte
-
-
Kwale County
-
Msambweni, Kwale County, Kenia, 80404
- Rekrutierung
- Msambweni District Hospital
-
Kontakt:
- Edith Mwasi, MD
- E-Mail: edithmwasi@gmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Subject's caregiver is willing and able to give informed consent
- Male or Female, 6 months (+/- 2 weeks) of age
- Mother ≥15 years of age
- Iron deficient (erythrocyte zinc protoporphyrin (ZnPP) >61 μmol/mol heme) or anemic (hemoglobin (Hb) <105 g/L)
Exclusion Criteria:
- Severely anemic (Hb <70 g/L)
- Hemoglobinopathies HbCC, HbSC, or HbSS
- Malaria, Measles or Typhoid vaccination prior to enrollment
- Medical condition that precludes study involvement
- Iron supplementation 2 weeks before enrollment
- Acute or chronic infection (e.g. HIV)
- Wasted (length for height z score of ≥-2) or underweight (weight for age z score ≥-2).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Iron treatment group
daily multivitamin + daily iron syrup from age 6 to 10 months |
Iron syrup administered daily from 6 to 10 months of age. Multivitamin syrup administered daily from 6 to 10 months of age. R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age. Measles-Rubella vaccine administered at 9 months of age. |
|
Sonstiges: Control group
daily multivitamin syrup from age 6 to 10 months |
Multivitamin syrup administered daily from 6 to 10 months of age. R21-Matrix/M vaccine administered in 3 doses at 7, 8 and 9 months of age. Measles-Rubella vaccine administered at 9 months of age. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
NANP-specific IgG
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG antibodies targeting the NANP repeat region of the circumsporozoite protein (CSP) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Anti-measles IgG
Zeitfenster: At 10 months of age (1 month after MR vaccine administration)
|
IgG antibodies targeting measles antigen |
At 10 months of age (1 month after MR vaccine administration)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Anti-typhoid IgG
Zeitfenster: At 10 months of age (1 month after Typhim VI administration)
|
IgG antibodies targeting typhoid antigen |
At 10 months of age (1 month after Typhim VI administration)
|
|
C-terminal-specific IgG
Zeitfenster: At 10 months of age (1 month after 3rd R21/Matrix-M dose)
|
IgG antibodies targeting the C-terminal region of CSP |
At 10 months of age (1 month after 3rd R21/Matrix-M dose)
|
|
C-terminal-specific IgG
Zeitfenster: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
IgG antibodies targeting the C-terminal region of CSP |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
C-terminal-specific IgG
Zeitfenster: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
IgG antibodies targeting the C-terminal region of CSP |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
|
NANP-specific IgG
Zeitfenster: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
IgG antibodies targeting the NANP repeat region of CSP |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
NANP-specific IgG
Zeitfenster: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
IgG antibodies targeting the NANP repeat region of CSP |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
|
Full-length CSP-specific IgG
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG antibodies targeting the full-length CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgM
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgM antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgA
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgA antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG4
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG4 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG3
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG3 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG2
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG2 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG1
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
IgG1 antibodies targeting the NANP repeat region of CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
IgG avidity to measles antigen
Zeitfenster: At 10 months of age (1 month after MR vaccine administration)
|
Avidity index for IgG binding to measles antigen |
At 10 months of age (1 month after MR vaccine administration)
|
|
IgG avidity to typhoid antigen
Zeitfenster: At 10 months of age (1 month after Typhim VI administration)
|
Avidity index for IgG binding to typhoid antigen |
At 10 months of age (1 month after Typhim VI administration)
|
|
IgG avidity to NANP-specific CSP
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Avidity index for IgG binding to NANP CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
IgG avidity to C-terminal CSP
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Avidity index for IgG binding to C-terminal CSP |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Full-length CSP-specific IgG seropositivity
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
C-terminal-specific IgG seropositivity
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
C-terminal-specific IgG seropositivity
Zeitfenster: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
C-terminal-specific IgG seropositivity
Zeitfenster: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
|
NANP-specific IgG seropositivity
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
NANP-specific IgG seropositivity
Zeitfenster: At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 9 months of age (1 month after the 2nd R21/Matrix-M dose)
|
|
NANP-specific IgG seropositivity
Zeitfenster: At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
Categorical (positive/negative) |
At 8 months of age (1 month after the 1st R21/Matrix-M dose)
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Inhibition of Plasmodium falciparum sporozoite-invasion of HC-04 hepatic cells
Zeitfenster: At 10 months of age (1 months after the 3rd R21/Matrix-M dose)
|
Exploratory in vitro assay on IgG functionality in lowest and highest responders |
At 10 months of age (1 months after the 3rd R21/Matrix-M dose)
|
|
Opsonic phagocytosis of CSP-coated beads by THP-1 cells
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Exploratory in vitro assay of IgG opsonization functionality in lowest and highest responders |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells
Zeitfenster: At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
Exploratory in vitro assay performed in lowest and highest responders |
At 10 months of age (1 month after the 3rd R21/Matrix-M dose)
|
|
Antibody levels against a panel of antigens associated with malaria exposure in the previous year
Zeitfenster: At 7 months of age (baseline)
|
Exploratory in all participants |
At 7 months of age (baseline)
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Nicole Stoffel, PhD, ETH Zurich
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Vektor-übertragene Krankheiten
- Durch Mücken übertragene Krankheiten
- Stoffwechselerkrankungen
- Infektionen
- RNA-Virusinfektionen
- Viruserkrankungen
- Protozoen-Infektionen
- Parasitäre Krankheiten
- Störungen des Eisenstoffwechsels
- Paramyxoviridae-Infektionen
- Mononegavirales-Infektionen
- Morbillivirus-Infektionen
- Ernährungs- und Stoffwechselerkrankungen
- Eisenmangel
- Malaria
- Masern
- Biologische Produkte
- Komplexe Gemische
- Impfungen
- Protozoen-Impfstoffe
- Malaria-Impfstoffe
Andere Studien-ID-Nummern
- MEMA
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .